<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585986</url>
  </required_header>
  <id_info>
    <org_study_id>ATO/PRO1</org_study_id>
    <nct_id>NCT02585986</nct_id>
  </id_info>
  <brief_title>Intervention Study to Evaluate a Probiotic in Mild Atopic Dermatitis Young Patients</brief_title>
  <official_title>Randomized, Double Blind, Placebo-controlled Intervention Study to Evaluate Safety and Efficiency of a Probiotic in Symptoms Reduction and Use of Topic Corticoids in Mild Atopic Dermatitis Patients Aged 4 to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biopolis S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korott, S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biopolis S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the beneficial effect of a probiotic preparation with an
      antiinflammatory and modulating activity on immunological processes, with positive results on
      different inflammatory and atopic conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators evaluate the safety and efficacy of a probiotic formulation
      in the reduction of symptoms and use of topic and systemic corticosteroids and antihistamines
      in the treatment of mild atopic dermatitis according to Hanifin and Rajka diagnostic criteria
      for atopic dermatitis, with a SCORAD (Scoring Atopic Dermatitis) index of 20 to 40, in
      patients 4 to 18 years old, that require the use of said drugs due to disease flare-ups, and
      to whom the usage of topic corticoids to control said flare-ups is indicated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of use of topic corticosteroids</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Duration of treatment with topic corticosteroids</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation in SCORAD score during treatment</measure>
    <time_frame>twelve weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation in the Global Clinical Impression (CGI) score during treatment</measure>
    <time_frame>twelve weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure to other treatments</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Duration of treatment with systemic corticosteroids or antihistamine drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects due to treatment in two arms of treatment</measure>
    <time_frame>twelve weeks</time_frame>
    <description>Number of side effects due to probiotic and due to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daily intake of 1 capsule containing probiotic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily intake of 1 capsule containing placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>daily intake of 1 capsule probiotic</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>Active formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>daily intake of 1 capsule containing placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients that are 4 to 17 years of age.

          -  Patients diagnosed of atopic dermatitis according to Hanifin and Rajka diagnostic
             criteria for atopic dermatitis.

          -  Patients with a SCORAD score ranging from 20 to 40.

          -  Patients that are actually using, or in which the use of topic corticosteroids to
             treat the atopic dermatitis flare-ups.

          -  Patients whose parents or legal representative have signed the informed consent. If
             the patient is 12 year old or older, the patient has to sign a consent to enter the
             trial.

        Exclusion Criteria:

          -  Pregnancy.

          -  Breastfeeding.

          -  Women of childbearing age that do not make a commitment to use any effective
             contraceptive method.

          -  Phototherapy treatments to atopic dermatitis

          -  Systemic corticoid therapy in the last two months.

          -  Immunosuppressive or cytostatic treatment in the last two months.

          -  Probiotic treatment in the last two months.

          -  Systemic antibiotic in the last four months.

          -  Fever (axillary temperature &gt; 37ºC or equivalent)

          -  Severe allergic diseases-

          -  Immunodeficiency or cancer related processes.

          -  Other dermatological pathologies that could difficult the atopic dermatitis
             evaluation, or that require the continued use of topic corticosteroids.

          -  Any contraindication to any product or drug used during the trial, according to their
             technical files.

          -  Participation in any drug clinical trial in the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Navarro-López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Católica San Antonio de Murcia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana A. Ramirez-Boscá, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Católica San Antonio de Murcia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Dermatologico Estetico de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Ellis C, Luger T, Abeck D, Allen R, Graham-Brown RA, De Prost Y, Eichenfield LF, Ferrandiz C, Giannetti A, Hanifin J, Koo JY, Leung D, Lynde C, Ring J, Ruiz-Maldonado R, Saurat JH; ICCAD II Faculty. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol. 2003 May;148 Suppl 63:3-10. Review.</citation>
    <PMID>12694268</PMID>
  </reference>
  <reference>
    <citation>Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003 Jan 11;361(9352):151-60. Review.</citation>
    <PMID>12531593</PMID>
  </reference>
  <reference>
    <citation>Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr 3;358(14):1483-94. doi: 10.1056/NEJMra074081.</citation>
    <PMID>18385500</PMID>
  </reference>
  <reference>
    <citation>Levy RM, Gelfand JM, Yan AC. The epidemiology of atopic dermatitis. Clin Dermatol. 2003 Mar-Apr;21(2):109-15. Review.</citation>
    <PMID>12706328</PMID>
  </reference>
  <reference>
    <citation>Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997 Feb;76(2):159-62.</citation>
    <PMID>9068310</PMID>
  </reference>
  <reference>
    <citation>Simpson EL, Hanifin JM. Atopic dermatitis. J Am Acad Dermatol. 2005 Jul;53(1):115-28.</citation>
    <PMID>15965431</PMID>
  </reference>
  <reference>
    <citation>Boguniewicz M, Leung DY. 10. Atopic dermatitis. J Allergy Clin Immunol. 2006 Feb;117(2 Suppl Mini-Primer):S475-80. Review.</citation>
    <PMID>16455350</PMID>
  </reference>
  <reference>
    <citation>Ridao M. Dermatitis atópica: clínica, diagnóstico diferencial y tratamiento. Pediatr Integral 2004:8:204-10.</citation>
  </reference>
  <reference>
    <citation>Hanifin JM, Rajka G. Diagnosis features of atopic dermatitis. Acta Derm Venereol 1980;92:44-7.</citation>
  </reference>
  <reference>
    <citation>Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23-31.</citation>
    <PMID>8435513</PMID>
  </reference>
  <reference>
    <citation>Sprikkelman AB, Tupker RA, Burgerhof H, Schouten JP, Brand PL, Heymans HS, van Aalderen WM. Severity scoring of atopic dermatitis: a comparison of three scoring systems. Allergy. 1997 Sep;52(9):944-9.</citation>
    <PMID>9298180</PMID>
  </reference>
  <reference>
    <citation>Charman C, Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol. 2000 Jun;136(6):763-9. Review.</citation>
    <PMID>10871941</PMID>
  </reference>
  <reference>
    <citation>Pucci N, Novembre E, Cammarata MG, Bernardini R, Monaco MG, Calogero C, Vierucci A. Scoring atopic dermatitis in infants and young children: distinctive features of the SCORAD index. Allergy. 2005 Jan;60(1):113-6.</citation>
    <PMID>15575941</PMID>
  </reference>
  <reference>
    <citation>Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol Venereol Leprol. 2006 Jul-Aug;72(4):315-21. Review.</citation>
    <PMID>16880586</PMID>
  </reference>
  <reference>
    <citation>National Institute for health and clinical excellence. Atopic eczema in children. Management of atopic eczema in children from birth up to the age of 12 years. NICE clinical guideline 57. Dec 2007.</citation>
  </reference>
  <reference>
    <citation>Boguniewicz M, Schmid-Grendelmeier P, Leung DY. Atopic dermatitis. J Allergy Clin Immunol. 2006 Jul;118(1):40-3. Epub 2006 Jun 6. Review.</citation>
    <PMID>16815136</PMID>
  </reference>
  <reference>
    <citation>Schoepe S, Schäcke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006 Jun;15(6):406-20. Review.</citation>
    <PMID>16689857</PMID>
  </reference>
  <reference>
    <citation>Castro AP. Calcineurin inhibitors in the treatment of allergic dermatitis. J Pediatr (Rio J). 2006 Nov;82(5 Suppl):S166-72. Review.</citation>
    <PMID>17136292</PMID>
  </reference>
  <reference>
    <citation>Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Bräutigam M; CASM-DE-01 study group. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205(3):271-7.</citation>
    <PMID>12399676</PMID>
  </reference>
  <reference>
    <citation>Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M; CASM-DE-01 Study Group. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology. 2004;208(4):365-72.</citation>
    <PMID>15178928</PMID>
  </reference>
  <reference>
    <citation>de Benedictis FM, de Benedictis D, Canonica GW. New oral H1 antihistamines in children: facts and unmeet needs. Allergy. 2008 Oct;63(10):1395-404. doi: 10.1111/j.1398-9995.2008.01771.x. Review.</citation>
    <PMID>18782118</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>September 11, 2016</last_update_submitted>
  <last_update_submitted_qc>September 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

